免疫检查点抑制剂治疗口腔鳞癌的研究进展

口腔鳞状细胞癌(Oral squamous cell carcinoma,OSCC)是口腔头颈部肿瘤的常见类型,显著的病理特征为免疫抑制和淋巴细胞的浸润。癌细胞常常通过激活不同的免疫检查点逃避免疫监视,从而躲过机体抗肿瘤免疫反应。目前的治疗方法都有一定的局限性,且毒副作用较大。因此,研究和开发新的治疗手段和给药途径尤为重要。免疫检查点抑制剂(Immune checkpoint inhibitors,ICIs)的引入带动了OSCC临床治疗模式的转变。在这篇综述中,我们讨论了抗细胞程序性死亡受体1(Programmed cell death protein 1,PD-1)治疗OSCC的优势,并综述了目前可用于预测疗效的生物标记物的相关进展。

Research progress of immune checkpoint inhibitors in the treatment of oral squamous cell carcinoma

Oral squamous cell carcinoma(OSCC)is a common type of oral head and neck tumors.The significant pathological features are immunosuppression and lymphocyte infiltration.Tumor cells often evade immune surveillance by activating different immune checkpoints,thereby avoiding the body′s anti-tumor immune response.The current treatment methods have certain limitations,and the side effects are relatively large.Therefore,it is particularly important to research and develop new treatment methods and routes of administration.The introduction of immune checkpoint inhibitors(ICIs)has led to a shift in the clinical treatment model of OSCC.This article discusses the advantages of the anti-programmed cell death protein 1(PD-1)in the treatment of OSCC,and reviews the current developments in biomarkers that can be used to predict efficacy.